Systemic and local immune responses to intraocular AAV vector administration in non-human primates
Open Access
- 22 January 2022
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 24, 306-316
Abstract
No abstract availableKeywords
All Related Versions
This publication has 47 references indexed in Scilit:
- Humoral Immune Response to AAVFrontiers in Immunology, 2013
- NET balancing: a problem in inflammatory lung diseasesFrontiers in Immunology, 2013
- Dosage Thresholds for AAV2 and AAV8 Photoreceptor Gene Therapy in MonkeyScience Translational Medicine, 2011
- Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsHuman Gene Therapy, 2010
- rAAV2/5 gene-targeting to rods:dose-dependent efficiency and complications associated with different promotersGene Therapy, 2010
- Safety and Efficacy of Subretinal Readministration of a Viral Vector in Large Animals to Treat Congenital BlindnessScience Translational Medicine, 2010
- Gene Therapy Using Adeno-Associated Virus VectorsClinical Microbiology Reviews, 2008
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Production of Recombinant Adeno‐Associated Viral Vectors for In Vitro and In Vivo UseCurrent Protocols in Molecular Biology, 2007